Close
Novotech
Jabsco PureFlo 21 Single Use

RBI seeks clarity on FII investment in pharmaceutical sector

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.
- Advertisement -

The Reserve Bank of India (RBI) has sought clarity on whether foreign portfolio investments can be allowed in existing companies without government approval, putting the spotlight back on a sector that has been the subject of much debate and policy change with respect to overseas investment.

 

The current policy for the pharma sector allows foreign direct investment (FDI) up to 100% through the automatic route in greenfield units, but investment in existing companies needs the approval of the Foreign Investment Promotion Board (FIPB).

The central bank has written to the finance ministry seeking to know the regime for foreign portfolio investment in listed Indian pharmaceutical companies – whether it can be allowed without prior FIPB approval. “The RBI basically wants clarity since there is a new regime in place for the pharma sector,” said a finance ministry official who didn’t want to be named. The ministry has initiated discussions with the Department of Industrial Policy and Promotion (DIPP), which has administrative charge of the FDI policy, to take a final call on the issue.

The distinction between greenfield projects and brownfield ones was introduced last year amid concern that Indians will be denied cheap medicines if multinationals continued to acquire control of local drug firms.

Foreign direct investment in the sector now attracts certain special conditions. These include having to manufacture and make available essential drugs for five years after the acquisition and to increase R&D expenditure by 5% for diseases prevalent in India.

Under the current rules, portfolio investment is allowed up to 24% in a listed company. It can be further raised to the sectoral limit through a board resolution and a special resolution of the shareholders. Individual portfolio investors can hold up to 10% in a company.

Experts do not see the need for FIPB approval for portfolio investments by foreign institutional investors. “FIPB approval requirements and FDI policy conditionalities should not apply to FII investments under the portfolio investment scheme. It would otherwise require specific amendment in FEMA (Foreign Exchange Management Act) regulations,” said Akash Gupt, executive director, PwC.

The RBI wants to play safe on the issue of foreign investment in the sector that has already seen intense debate within the government.

A similar issue about adhering to sectoral conditions had also cropped up with respect to portfolio investment in multi-brand retail. A proposal by Future Retail to raise portfolio investment in the venture was directed by the RBI to FIPB and then to DIPP. It is still pending approval. An official said the issue is expected to get resolved once the Arvind Mayaram panel on aligning the definition of FDI and portfolio investment gives its report.

Latest stories

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

White House-Big Pharma Tariff and Pricing Deals in 2026

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »